Phosphatidylserine, Dementia, Cognitive Decline Health Claim Sought
This article was originally published in The Tan Sheet
Executive Summary
No particular dose of phosphatidylserine works better at reducing the severity of cognitive dysfunction and the risk of dementia, according to a health claim petition filed with FDA April 19
You may also be interested in...
Selenium Cancer Risk Reduction Qualified Claims To Be Allowed By FDA
Health claims linking selenium supplements with reducing cancer risk will be permitted by FDA through its "enforcement discretion," according to the agency
Seleniun/cancer claim
Supplement maker Wellness Lifestyles d/b/a American Longevity seeks FDA approval of health claims stating selenium "may reduce the risk of certain cancers" and "may produce anticarcinogenic effects in the body." Petition filed July 10 notes claims "do not identify specific intake quantities for selenium," although studies have shown risk reduction with 50-200 mcg/day. Adult daily intake below 900 mcg "is unlikely to cause adverse reactions," Wellness adds. Petition cites six human clinical trials (three in China, and one each in U.S., India, Italy) on selenium supplementation and cancer incidence. Firm is represented by Emord & Associates (Washington, D.C.), which filed a health claim petition for phosphatidylserine and cognitive dysfunction/dementia in April (1"The Tan Sheet" May 6, 2002, p. 10)...
SSA Guidance Provides Review Methods, Not Definition
Research findings that are "not likely to be reversed" by future study results would be required to support a health claim under FDA's guidance on the "significant scientific agreement" standard for dietary supplements and conventional foods.